Differential effects of interleukin-7 and interleukin-15 on NK cell anti-human immunodeficiency virus activity.
about
Slow turnover of HIV-1 receptors on quiescent CD4+ T cells causes prolonged surface retention of gp120 immune complexes in vivoBeneficial effect of TRAIL on HIV burden, without detectable immune consequences.Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.Diverse interleukin-7 mRNA transcripts in Chinese tree shrew (Tupaia belangeri chinensis).The TRAIL to viral pathogenesis: the good, the bad and the uglyThe Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious DiseasesIsolation of a TRAIL antagonist from the serum of HIV-infected patients.Timely triggering of homeostatic mechanisms involved in the regulation of T-cell levels in SIVsm-infected sooty mangabeysS100A9 Tetramers, Which are Ligands of CD85j, Increase the Ability of MVAHIV-Primed NK Cells to Control HIV Infection.Soluble mediators of inflammation in HIV and their implications for therapeutics and vaccine developmentInterleukin-7 induced immunopathology in arthritis.Innate immune defenses in HIV-1 infection: prospects for a novel immune therapy.Altering cell death pathways as an approach to cure HIV infection.The expanding role of IL-7 and thymic stromal lymphopoietin as therapeutic target for rheumatoid arthritis.CD56bright NK IL-7Rα expression negatively associates with HCV level, and IL-7-induced NK function is impaired during HCV and HIV infections.Maintenance of the HIV Reservoir Is Antagonized by Selective BCL2 Inhibition.Distinctive in vitro effects of T-cell growth cytokines on cytomegalovirus-stimulated T-cell responses of HIV-infected HAART recipients.Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections.Interleukin-7 signalling is sufficient to phenotypically and functionally prime human CD4 naive T cells.Juxtacrine function of interleukin-15/interleukin-15 receptor system in tumour derived human B-cell lines.
P2860
Q27330487-3537A8DB-4A15-4459-AA36-9CAF9CA0C63EQ33366417-BBD16E44-4D8E-4886-AF46-6AA255F8A1D8Q33760403-1065BB37-2560-455F-AB15-81E961BC2552Q33779048-0916D012-710D-42A8-99C8-FB8CB2299893Q35146349-61C40201-2F16-4499-AB2F-AC8D0C56DDFFQ35172090-DA7B0270-6D93-4035-BAD6-6A862432B52FQ35372514-B62337E2-1FB9-4D1B-955C-EDB2EE8D9B81Q35847795-428C99FF-EFFD-48DE-9E0A-754352467C8DQ36098116-4E7CDDF5-E29B-4D61-8028-A58AB3BA5448Q36162133-306E6245-5C7A-42E9-AF41-BE75EE83C888Q36622402-E675B6DD-3729-4B12-AC23-ACB1E250CA5EQ36670882-2F0EC613-B82F-49ED-9E0B-EF8FBD449673Q37062057-5E8827AB-FEE6-47AA-84EA-E83BCCE313BEQ38196882-7CDB35C9-4A99-4C17-8EB5-8779D2E04704Q40246889-3970CCB8-FB29-4FE2-A15F-08A9E0EC5953Q40279377-D82E2779-511A-4137-A75C-11D1516A9537Q41339628-29965D79-9F2C-4148-B73C-415E37BD80D6Q41904728-DE812BB4-EC78-4259-9B59-F6F90D86E385Q48953968-409E28A0-8D51-4608-BE48-B72336EE7965Q54571746-12932A27-1E55-47FC-9293-678BF121499E
P2860
Differential effects of interleukin-7 and interleukin-15 on NK cell anti-human immunodeficiency virus activity.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Differential effects of interl ...... munodeficiency virus activity.
@ast
Differential effects of interl ...... munodeficiency virus activity.
@en
Differential effects of interl ...... munodeficiency virus activity.
@nl
type
label
Differential effects of interl ...... munodeficiency virus activity.
@ast
Differential effects of interl ...... munodeficiency virus activity.
@en
Differential effects of interl ...... munodeficiency virus activity.
@nl
prefLabel
Differential effects of interl ...... munodeficiency virus activity.
@ast
Differential effects of interl ...... munodeficiency virus activity.
@en
Differential effects of interl ...... munodeficiency virus activity.
@nl
P2093
P2860
P1433
P1476
Differential effects of interl ...... munodeficiency virus activity.
@en
P2093
Andrew D Badley
David H Lynch
David J Schnepple
Georgina L Mbisa
Jaime Sanchez-Dardon
Jennifer Mihowich
John E Kim
Julian J Lum
Nanci Hawley
Shanil Narayan
P2860
P304
P356
10.1128/JVI.78.11.6033-6042.2004
P407
P577
2004-06-01T00:00:00Z